A consortium of banks has reduced borrowing costs on $8.5 billion of leveraged loans backing the Hologic Inc. buyout. The move reflects intense investor demand for high-yield debt instruments despite elevated risk levels in today's market.

Medical-device companies have attracted steady private equity interest due to recurring revenue streams and defensive healthcare spending. Hologic's strong market position in diagnostics and women's health products made it an attractive LBO target amid ongoing sector consolidation.

Investors are paying close attention to how loan pricing adjustments affect overall deal economics. The tightening spreads suggest competitive bidding among lenders eager to secure fee income from large-cap buyouts during uncertain economic conditions.